In partnership with Cardiff University, the U.K.-based company Cytox has been awarded funding by Innovate U.K. to evaluate and validate the clinical utility of a customized single nucleotide polymorphism (SNP) panel associated with the development of Alzheimer’s disease. As part of this project, the two organizations will develop, optimize, and test a set of polygenic risk score approaches and then implement them on Cytox’s proprietary software platform. Subsequently, the algorithms will be tested in large cohorts of patients with mild cognitive impairment and cognitively normal subjects, such as a recently well-characterized 500 patient subset of a 1946 birth cohort, to demonstrate the validity of a panel of identified at-risk Alzheimer’s biomarkers. Overall, the project aims to confirm that a proprietary SNP panel and associated algorithm is an effective method for predicting the presence of Alzheimer’s pathology. The Innovate U.K. award provides £800,000 ($1.3 million) out of a total project value of £1 million ($1.6 million) over 2 years.